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Abstract
Background: The retroperitoneal margin is a common site of positive surgical margins in patients with resectable
pancreatic cancer. Preoperative margin-intensive therapy (MIT) involves delivery of a single high dose of ablative
radiotherapy (30 Gy) focused on this surgically inaccessible margin, utilizing stereotactic techniques in an effort to
reduce local failure following surgery. In this study, we investigated the motion of regional organs at risk (OAR)
utilizing 4DCT, evaluated the dosimetric effects of abdominal compression (AC) to reduce regional motion, and
compared various planning techniques to optimize MIT.
Methods: 10 patients were evaluated with 4DCT scans. All 10 patients had scans using AC and seven of the 10
patients had scans both with and without AC. The peak respiratory abdominal organ and major vessel centroid
excursion was measured. A “sub-GTV” region was defined by a radiation oncologist and surgical oncologist
encompassing the retroperitoneal margin typically lateral and posterior to the superior mesenteric artery (SMA),
and a 3-5 mm margin was added to constitute the PTV. Identical 3D non-coplanar SABR (3DSABR) plans were
designed for the average compression and non-compression scans. Compression scans were planned with
3DSABR, coplanar IMRT (IMRT), and Cyberknife (CK) planning techniques. Dose volume analysis was undertaken for
various endpoints, comparing OAR doses with and without AC and for different planning methods.
Results: The mean PTV size was 20.2 cm
3. Regional vessel motion of the SMA, celiac trunk, and renal vessels was
small (< 5 mm) and not significantly impacted by AC. Mean pancreatic motion was > 5 mm, so AC has been used
in all patients enrolled thus far. AC did not significantly increase OAR dose including the stomach and traverse
colon. There were several statistically significant differences in the doses to OARs as a function of the type of
planning modality used.
Conclusions: AC does not significantly reduce the limited motion of structures in close proximity to the MIT target
and does not significantly increase the dose to OARs that can be displaced by the compression plate. The
treatment planning techniques evaluated in this study have different advantages with no clearly superior method
in our analysis. Dose to adjacent vessels may be reduced with 3DSABR or IMRT techniques, while conformality is
increased with IMRT or CK.
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An estimated 43,000 people in the United States were
diagnosed with pancreatic ductal adenocarcinoma (PA)
in 2010 [1]. PA is the fourth leading cause of cancer-
related death in the US, with over 36,000 deaths in
2010.
1 The majority of patients with PA present with
metastatic disease at the time of diagnosis with a med-
ian survival of 3-6 months [2]. While approximately 20-
25% of patients are diagnosed with localized disease that
is amenable to surgical resection,[2] even these patients
that undergo surgical resection have a 5 year survival
rate of less than 20% [3]. Following surgical resection of
PA originating in the head of the gland, at least 20% of
patients will have positive margins, typically located in
the retroperitoneal space medial and posterior to the
pancreas, and 65% of patients will have involved lymph
nodes [4]. Positive surgical margins in these patients is a
poor prognostic factor and associated with decreased
survival [5]. Following surgical resection, local failure
can occur in 50-80% of patients, with the retroperitoneal
margin as the most common location of isolated local
failure [6-11].
Because of the high incidence of local failure in surgi-
cally resected PA, radiation therapy has been investi-
gated both preoperatively and postoperatively as
adjuvant therapy to help reduce this risk in patients
with potentially curable disease [12-18]. Some of these
trials showed a benefit to adjuvant radiation therapy fol-
lowing surgical resection, while others showed a detri-
ment or no benefit, leading to controversy surrounding
the role of radiation therapy in addition to chemother-
apy for patients with surgically resected disease. Patients
with early dissemination of disease would not benefit
from additional local therapy such as radiation, making
it difficult within this patient population to show a sur-
vival advantage to radiation even if local control is
improved. In contrast to radiation therapy, important
trials have demonstrated a clear survival benefit to adju-
vant chemotherapy following surgical resection, leading
to standardization of chemotherapy as adjunctive ther-
apy in these patients [19]. Thus, current ideal treatment
of patients with resectable PA includes complete surgi-
cal resection with early delivery of adjuvant chemother-
apy to address systemic disease.
New radiation techniques may be exploited to allow
the local control benefits of radiation therapy to be
administered without significantly delaying systemic che-
motherapy or causing decline related to toxicity. Stereo-
tactic ablative radiotherapy (SABR), also known as
stereotactic body radiation therapy (SBRT), utilizes
advanced techniques of immobilization, image guidance,
and unique field arrangements to deliver precise, oligo-
fractionated radiotherapy to a variety of tumor types.
SABR has been established as a technologically
innovative therapy for early stage non-small cell lung
cancer (NSCLC) and has emerged as the standard treat-
ment option for medically inoperable patients through
prospective, multi-institutional trials [20,21]. SABR for
locally advanced, unresectable pancreatic cancer has
been investigated in both phase I and II trials [22-24].
In these trials, doses ranging from 15-45 Gy in 1-3 frac-
tions were administered to the primary tumor in
patients with locally advanced, unresectable PA. In one
phase II trial, 45 Gy in 3 fractions was used to treat the
entire primary, unresectable tumor plus margin, but
associated toxicity was high in this group of 22 patients
[24]. Increased levels of grade 2 and greater nausea and
pain were seen in a significant proportion of treated
patients, leading to decline in performance status, and
increased analgesic use. In four patients, severe mucosi-
tis or ulceration of the stomach or duodenum was
observed on post-treatment endoscopy. Another phase
I/II experience had more encouraging results for use of
SABR in locally advanced PA when treated with smaller
margins again in unresectable disease [22,23]. The phase
I portion of the trial escalated single doses of radiation
from 15 to 25 Gy delivered with the Cyberknife
® radio-
surgery system with no grade 3 or higher toxicity
observed. The phase II portion of the trial treated
patients with fractionated IMRT and 5-FU chemother-
apy prior to a SABR boost of 25 Gy based on the phase
I experience. Two out of 16 patients experienced grade
3 toxicity consisting of gastroparesis. Again, duodenal
ulcers were seen 4-6 months after treatments, though all
were managed medically. Median survival was 33 weeks
for the 16 patients. This trial demonstrated the feasibil-
ity of utilizing SABR as a boost for locally advanced dis-
ease, and although local control rates were promising
for this limited experience, overall survival did not seem
to improve over expected rates observed with conven-
tional chemoradiation. Each of these trials studied
patients with larger, unresectable tumors, with signifi-
cant irradiated volumes required to treat the entire
tumor plus margin. As a consequence, relatively radio-
sensitive normal organs at risk (OAR) such as the duo-
denum, distal stomach, and remaining small bowel
limited tolerance of SABR.
We define Margin Intensive Therapy (MIT) as a new
concept that delivers ablative doses of radiation only to
the tumor border around unresectable structures such
as the superior mesenteric artery (SMA) and retroperi-
toneal margin preoperatively with the goal of reducing
t h ep o s i t i v em a r g i nr a t ea n d ,h e n c e ,l o c a lf a i l u r er a t ei n
this area. As opposed to conventional radiation for PA
which includes a the entire tumor and regional lymph
nodes in the treatment volume, MIT focuses an single
ablative dose (e.g., 30 Gy) of radiation to a very small at
risk area in contrast to traditional delivery of 50.4 Gy in
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Page 2 of 1128 fractions to the pancreatic tumor and regional lymph
nodes. MIT complements surgery as it treats the area
most difficult for surgeons to resect and obtain clear
margins. To deliver MIT, stereotactic techniques are
used, but unlike the previous trials exploring SABR for
locally advanced PA, MIT delivers dose away from sen-
sitive structures such as the duodenum that have led to
high toxicity levels in previous trials. By delivering the
dose in a single fraction, surgical resection will not be
delayed in these patients, who can go on to receive adju-
vant systemic therapy without delay after recovery.
To explore the concept of MIT, we have initiated a
phase I trial at our institution evaluating the safety and
toxicity of preoperative MIT followed by surgical resec-
tion with pancreaticoduodenectomy in patients with
newly diagnosed, resectable PA. This is novel use of
SABR in its targeting of a high risk subvolume in oper-
able patients rather than the entire tumor in unresectable
patients. Additionally, the respiratory associated motion
of structures in close proximity to the target volume for
PA has not been thoroughly explored. The effect of
abdominal compression as a tool to reduce respiratory
tumor motion, as is used at our institution,[25] on
unique adjacent structures such as the SMA and renal
vessels is also unknown. Because abdominal compression
may displace OARs such as the transverse colon, sto-
mach, and small intestine towards the target, there may
be an effect on dose to these structures when abdominal
compression is utilized in MIT. Finally, since many plan-
ning techniques can be utilized to deliver MIT with
SABR methods, we performed a planning comparison for
this novel concept in an attempt to optimize MIT.
Methods
Patient selection
For these comparisons, we chose six patients who pre-
viously had 4D CT scans taken with and without
abdominal compression as previously described [25].
These patients did not have PA; most were treated with
SABR for lung primary or metastatic tumors. However,
since the target volume was based on the vessel location
and the retroperitoneal margin of the pancreatic head,
PA was not needed for volume delineation in this study.
In addition to these 6 patients, the first 4 patients
enrolled on the phase I trial then underwent 4D CT
scans. This is an ongoing clinical trial that has been
approved by the Institutional Review Board in compli-
ance with the Helsinki Declaration. In total 7 patients
had 4DCT scans both with and without AC, and 3
patients had scans with AC only (total 10 patients).
Patients eligible for the trial had pathologically con-
firmed PDAC with surgically resectable disease as deter-
mined by a surgical oncologist at our institution based
on CT or MRI of the abdomen.
4D-CT Scan Acquisition and Reconstruction
Patients were simulated in an Elekta Stereotactic Body
Frame
® as described previously [26]. All 4D scans were
acquired with the Philips Brilliance 190P multi-slice 4D-
CT scanner (Philips Medical Systems, Bothell, WA).
The respiratory cycle signal was acquired using the Bel-
lows System (Philips Medical Systems, Bothell, WA).
This system uses an elastic strap that was attached to
the abdominal or thoracic region and correlates chest
wall motion with the respiratory cycle. Phase sorting
was performed and images from the 10 phases were
automatically reconstructed by the Philips software. The
phases were defined as 0% to 100% corresponding to
the point in the respiratory cycle which the images
represented with 0% representing peak inspiration. In
addition, the peak expiratory phase was reconstructed
based on the respiration cycle data analyzed by the Phi-
lips software. All phases were evaluated within the Phi-
lips CT viewing system to ensure that the maximum
diaphragmatic and tumor movement were represented
by the peak inspiratory and expiratory phases. This pro-
cedure was repeated consistently for both the AC and
non-compression (NC) 4D CT scans.
Evaluation of tumor and organ motion
The CT series representing peak inspiration and peak
expiration were transferred to the Philips Pinnacle v8.0
m
® treatment planning system for viewing. Image
fusion was used to ensure correlation between the two
CT series. Automatic image fusion was performed initi-
ally and evaluated using manual fusion of the frame
fiducials. Within the peak inspiration CT series, the kid-
neys, pancreas, liver, spleen, SMA, renal vessels, liver,
stomach, and duodenum were contoured. These con-
tours were then transferred onto the peak expiratory
phase and adjusted to fit the position of these same
structures at that point of the respiratory cycle. A point
of interest representing the centroid point of that parti-
cular structure’s contour was then generated for each
structure in both respiratory phases. The position of the
centroid points were then compared to determine the
peak movement of each structure in the SI, lateral, and
anterior-posterior (AP) directions. Overall movement
was calculated as the magnitude of the vector of the
three directions. Motion in all three directions along
with overall vector motion was compared with the AC
and NC scans utilizing a two-tailed paired t-test with
significant differences defined as p < 0.05.
Evaluation of Dosimetric Effect of Abdominal
Compression on OARs
Average intensity projection CT scans were recon-
structed from both the AC and NC 4D CT scans for the
10 patients and imported into Pinnacle v8.0 m. Seven of
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analysis and all 10 patients had AC 4D CT scans avail-
able. All patients were scanned supine with arms
above their head utilizing IV contrast. The “sub-GTV”
( F i g u r e1 )t a r g e tv o l u m ew a sd e f i n e db yt h er a d i a t i o n
oncologist and surgical oncologist consisting of a small
volume typically posterior and lateral to the SMA that
included the projected surgical margin of resection and
any retroperitoneal or peripancreatic nodal tissue in
the area of the tumor but outside the anticipated feasi-
ble resection field. This volume was then expanded in
all directions by 3 mm in the axial plane and 5 mm in
the superior-inferior direction to constitute the PTV.
Organs at risk including the liver; stomach; duodenum;
small bowel; ascending, descending, and traverse colon;
SMA, renal vessels, celiac trunk, kidneys, and spinal
cord were identified and contoured on both scans.
Identical 3D conformal SABR (3DSABR) plans were
then constructed for both AC and NC studies. These
plans consisted of 10 non-coplanar beams with confor-
mal blocking to the PTV. We typically employ a nega-
tive margin blocking scheme to create an isotropic
dose falloff around the target [26]. The prescription
dose was 30 Gy in 1 fraction as was planned in the
phase 1 trial, and plans were prescribed to the 65-85%
isodose line to ensure that 95% of the PTV volume
was covered by 100% of the prescription dose and that
99% of the PTV volume was covered by 90% of the
prescription dose. Doses to the contoured OARs were
then compared for the AC and NC plans utilizing a
two-tailed paired t-test. Differences were considered
significant for p < 0.05.
Comparison of Dosimetric Outcomes for Three Different
Planning Methods
Average intensity projection AC scans were then
planned utilizing three different planning techniques.
The first planning technique was 3DSABR is described
above. Additionally, a coplanar IMRT (IMRT) plan was
generated in Pinnacle utilizing 13 coplanar beams direc-
ted at the PT was generated. Objectives were created for
the duodenum, liver, small bowel, and spinal cord to
meet institutional constraints for single-fraction SABR
to 30 Gy in 1 fraction (Table 1). Plans were prescribed
based on coverage parameters identical to those of
3DSABR. Finally, Cyberknife
® (CK) plans were gener-
ated for all 10 patients after exporting average scans and
contours to the MultiPlan
® treatment planning system
v. 4.0 (Accuray, Sunnyvale, CA). Plans were generated
utilizing the sequential optimization function typically
with 2 collimators based on PTV size (typically 15 mm
and 25 mm). Objectives were defined based on OAR
constraints and PTV conformality as described above
for IMRT planning. Plans were again assessed based on
the coverage parameters above, typically to the 60-70%
isodose line.
Dosimetric analysis and statistical methods
Dose volume results for 3DSABR, IMRT, and CK plans
for each patient were recorded and included maximum,
minimum, and mean dose for the contoured OARs. Spe-
cific dose-volume relationships including dose to 5 cc of
the duodenum, 5 cc of the non-duodenum small intes-
tine, 10 cc of the stomach, 100 cc of the bilateral kid-
neys, 700 cc of the liver, 20 cc of the colon, and 0.3 cc
Figure 1 “Sub-GTV” volume is shown in green. Small volume lateral and posterior of the pancreatic head tumor (red arrow). Volume is
significant distance from sensitive structures such as duodenum (white arrow).
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formality index (CI) was calculated for each planning
technique by calculating the ratio of the volume receiv-
ing the prescription dose (30 Gy) to the PTV volume. A
two tailed paired t test was used to compare doses for
parameters above for each of the three planning meth-
ods. Differences were considered significant for p <
0.01667 based on a Bonferroni correction for level of
the p-value significance.
Results
Patient characteristics
Thus far, 4 patients have been enrolled on the phase I
trial and each received 30 Gy in 1 fraction to the PTV
followed by surgical resection. All patients met eligibility
criteria as described above. The primary endpoints of
the trial include preoperative toxicity and postoperative
surgical morbidity. As described above, 6 other patients
were included in this analysis not enrolled on the phase
I trial that had previous 4D CT scans with and without
AC for analysis of motion and planning techniques. The
m e a ns u b - G T Vs i z ef o rt h e1 0p a t i e n t sw a s4 . 4c m
3
(3.4-6.6 cm
3) and the mean PTV size was 20.2 cm
3
(15.6-24.9 cm
3).
Motion Analysis
For each organ, mean motion values for all three direc-
tions and vector motion with and without AC are
shown in Table 2. Motion of structures adjacent to the
PTV, including the SMA and renal vessels had very little
respiratory-associated motion. For the trial, AC was
used in all patients based on motion of fiducial markers
place in the head of the pancreas with motion evaluated
with fluoroscopy. AC did not significantly affect motion
of most organs, but did significantly reduce AP motion
of the stomach (p = 0.009), AP motion of the pancreas
(p = 0.009), and vector motion of the SMA (p = 0.02).
Dosimetric Effect of Abdominal Compression
Mean doses to the contoured OARs for the same
3DSABR plan for patients with and without AC are
shown in Table 3. AC did not significantly increase
minimum, mean, or maximum doses to any of the
OARs including the stomach or transverse colon which
can be displaced towards the target by the AC plate.
Comparative dosimetric analysis
A total of thirty plans were generated for this compari-
son, including 10 3DSABR, 10 IMRT, and 10 CK plans
and were evaluated for CI and OAR dose volume criteria
of interest. All plans met the basic dosimetric constraints
used for this trial (Table 1). Figures 2, 3, and 4 show
examples of 3DSABR, IMRT, and CK plans for the same
patient for the described PTV volume. Results for signifi-
cant differences between various dosimetric parameters
are illustrated in Table 4. 3DSABR was superior to IMRT
for the mean dose to the left renal vessels (6.3 vs. 9.5 Gy)
(p = < 0.001), and mean (4.6 vs. 9.1 Gy) (p = 0.004) and
maximum (15.1 vs. 20.6 Gy) (p = 0.003) doses to the
right renal vessels. 3DSABR was superior to CK for the
mean dose to the left renal vessels (6.3 vs. 8.3 Gy) (p =
0.002). CK was superior to IMRT for dose to 20 cc of the
transverse colon (4.1 vs. 7.7 Gy) (p = 0.003). CK was
superior to 3D SABR with respect to the target conform-
ality index (CI) (1.19 vs. 1.29) (p = 0.008) and the dose to
20 cc of the transverse colon (4.1 vs. 5.8 Gy) (p = 0.003).
IMRT was superior to 3D SABR for the mean dose to the
liver (82 vs. 109 cGy) (p = < 0.001), max dose (30.7 vs.
36.0 Gy) (p = < 0.001) and mean dose (27.4 vs. 29.5 Gy)
(p = 0.015) to the SMA, and CI (1.15 vs. 1.29) (p =
0.001). IMRT was superior to CK for the maximum dose
to the celiac trunk (29.6 vs. 33.7 Gy) (p = 0.007), and the
maximum (30.6 Gy vs. 35.7 Gy) (p = 0.001) dose to the
SMA. Other reported significant outcomes are shown in
Table 4.
Table 1 OAR dose constraints used for planning for the phase I trial
Critical Structure Dose Limits
Serial Tissue Volume Volume Max
(Gy)
Max Point Dose
(Gy)
Endpoint (≥ Grade 3)
Spinal Cord and medulla < 0.35 cc 10 Gy 14 Gy myelitis
< 1.2 cc 7 Gy
Spinal Cord Subvolume (5-6 mm above and below level
treated)
< 10% of
subvolume
10 Gy 14 Gy myelitis
Skin < 10 cc 23 Gy 26 Gy ulceration
Stomach < 10 cc 11.2 Gy 12.4 Gy ulceration/fistula
Duodenum* < 5 cc
<1 0c c
11.2 Gy
9G y
12.4 Gy ulceration
Jejunum/Ileum* < 5 cc 11.9 Gy 15.4 Gy enteritis/obstruction
Colon* < 20 cc 14.3 Gy 18.4 Gy colitis/fistula
Liver 700 cc 9.1 Gy Basic Liver Function
Renal cortex (Right & Left) 200 cc 8.4 Gy Basic renal function
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PA continues to be a leading cause of cancer related
death in the U.S. with the majority of patients present-
ing with metastatic, incurable disease [1,2]. Despite
improved imaging techniques utilized preoperatively to
assess the likelihood of achieving a margin-negative
surgical resection, about 20% or more of patients will
have positive margins after pancreatoduodencetomy,
with many more having “close” (1-2 mm) margins [4,5].
The main margin of interest for pancreatic head tumors
is the retroperitoneal surgical margin, defined here as
the tissue adjacent to the proximal SMA [27]. This
Table 2 Mean motion and ranges in cm for regional structures without (top) and with (bottom) abdominal
compression
Mean Motion without compression (cm)
Organ AP Range Lat Range SI Range Vect Range
Liver 0.07 0.02-0.17 0.41 0.16-0.53 0.82 0.42-1.74 0.95 0.50-1.82
Spleen 0.18 0.14-0.30 0.32 0.26-0.68 0.70 0.11-1.87 0.84 0.37-2.00
Stomach 0.19 0.01-0.42 0.26 0.15-0.46 0.60 0.4-0.99 0.76 0.62-1.01
Duodenum 0.20 0.02-0.27 0.25 0.03-0.68 0.49 0.06-1.02 0.58 0.18-1.26
Pancreas 0.29 0.02-0.26 0.24 0.10-0.38 0.52 0.12-0.89 0.68 0.32-0.98
Celiac trunk 0.14 0.08-0.27 0.23 0.04-0.42 0.28 0.07-0.75 0.39 0.22-0.90
SMA 0.13 0.06-0.46 0.21 0.04-0.48 0.24 0.07-0.45 0.42 0.39-0.65
R kidney 0.08 0.01-0.08 0.28 0.03-0.55 0.64 0.19-0.82 0.60 0.19-0.99
L kidney 0.06 0-0.14 0.09 0-0.28 0.32 0.11-0.74 0.37 0.16-0.80
R renal vessels 0.21 0.05-0.42 0.33 0.36-0.41 0.54 0.31-1.32 0.70 0.58-1.39
L renal vessels 0.29 0.03-0.33 0.12 0.03-0.26 0.38 0.21-0.93 0.57 0.24-1.02
Mean motion with compression (cm)
Organ AP Range Lat Range SI Range Vect Range
Liver 0.11 0.08-0.19 0.23 0.03-0.66 0.48 0.2-0.68 0.56 0.25-0.97
Spleen 0.19 0.01-0.32 0.22 0.08-0.67 0.63 0.06-1.25 0.71 0.10-1.45
Stomach 0.16 0-0.28 0.11 0.05-0.23 0.36 0.08-0.46 0.46 0.14-0.50
Duodenum 0.10 0.02-0.19 0.09 0.01-0.27 0.36 0.06-0.58 0.40 0.07-0.61
Pancreas 0.28 0.02-0.89 0.08 0.01-0.1 0.40 0.08-0.57 0.54 0.13-0.90
Celiac trunk 0.13 0-0.49 0.12 0.01-0.25 0.23 0-0.30 0.32 0.01-0.60
SMA 0.11 0.04-0.17 0.09 0.01-0.17 0.15 0-0.27 0.24 0.10-0.28
R kidney 0.05 0.04-0.21 0.19 0.12-0.48 0.52 0.08-1.59 0.56 0.17-1.67
L kidney 0.05 0.01-0.07 0.12 0-0.12 0.45 0.09-0.92 0.48 0.12-0.93
R renal vessels 0.15 0.03-0.31 0.22 0.03-0.43 0.46 0.23-0.87 0.56 0.41-0.89
L renal vessels 0.24 0.01-1.15 0.18 0.06-0.36 0.33 0.04-0.54 0.52 0.16-1.28
Table 3 Doses in cGy for regional OAR for 3DSBRT plans on simulation scans with and without AC
Organ Mean dose without AC (cGy) Mean dose with AC (cGy) p value
L kidney 196.8 172.7 0.48
L renal vessels 701.8 629.8 0.70
R kidney 182.3 218.3 0.36
R renal vessels 397.9 460.6 0.60
Ascending colon 135.2 141.4 0.86
Celiac trunk 2459.0 2214.9 0.49
Spinal cord 233.4 248.7 0.76
Descending colon 121.9 133.2 0.78
Duodenum 484.8 531.0 0.48
Liver 132.9 108.7 0.27
SMA 2818.4 2951.8 0.77
Small bowel 235.2 238.3 0.95
Stomach 159.9 121.8 0.17
Transverse colon 192.9 197.8 0.90
Heinzerling et al. Radiation Oncology 2011, 6:146
http://www.ro-journal.com/content/6/1/146
Page 6 of 11space is invested with lymphatics and a rich plexus of
nerves, and pancreatic tumor cells can infiltrate the
perineural spaces making complete surgical excision
impossible without excision of the artery itself in many
cases [28]. Autopsy and clinical series have demon-
strated high rates of residual tumor around the SMA
and that these areas can grow as true local recurrences
visible on CT [6-8,29]. Using a definition that tumor
within 1 mm of the inked surgical specimen constituted
a ‘positive margin’ Esposito et al showed that 76% of
patients undergoing resection for PA had an R1 surgery
[30]. Using the same criteria, Verbeke et al found the
posterior resection margin to be involved in more than
50% of cases [31]. Our ‘sub-GTV’ was designed to
encompass this high-risk soft tissue volume for pancrea-
tic head tumors.
Given the high rates of close and positive margins and
the attendant high rates of local failure, adjuvant fractio-
nated radiation, typically delivered concurrently with
chemotherapy, is commonly employed in the treatment
of resected pancreatic cancer. Despite evidence that
radiation does reduce local failure after surgical
resection, adjuvant radiation has associated toxicities
and can delay initiation of “full-dose"systemic therapy
[9]. Moreover, positive surgical margins in the retroperi-
toneal area may portend aggressive disease biology that
will minimize the chance that local therapy will improve
survival. “Clearing” the retroperitoneal margin can be
accomplished with resection oft h eS M Ai t s e l f ,b u tt h i s
has not, in general, been associated with high rates of
long-term disease-free survival [32]. In other words,
patients may indeed experience local failure, but typi-
cally in the setting of distant disease failure as well, with
the latter ultimately leading to patient death. As sys-
temic therapies continue to improve, however, the value
of local control will likely increase. In addition, patients
with close (< 2 mm) but technically negative surgical
margins may benefit from aggressive adjuvant local ther-
apy as they are at risk for harboring small-volume resi-
dual disease not seen on histopathologic evaluation.
New technological advancements in radiation therapy,
such as those utilized in SABR, allow delivery of high-
dose oligofractionated treatments, leading to reduction
in time and inconvenience for patients. These
Figure 2 Example of 3DSABR plan in axial and sagittal planes.
Figure 3 Example of coplanar IMRT plan in axial and sagittal planes.
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sectable PA, but not as adjunctive treatment in surgi-
cally resectable disease [22-24]. Previous experience with
SABR in PA has exposed some of the limitations when
performing high dose per fraction treatment near radio-
sensitive normal structures such as the duodenum. Yet,
if an area at high risk of true local failure (the retroperi-
toneal margin space) were targeted instead of the entire
tumor burden, these normal tissues could be spared to a
greater extent than in these prior experiences. In addi-
tion, if SABR techniques are used, radiation can be
delivered in a single fraction (as in our study), or a few
fractions, leading to reduction of treatment time and the
delay in time to receiving chemotherapy in these
patients. These hypotheses have driven exploration of
neoadjuvant ablative SABR in a single fraction focusing
on targeting the retroperitoneal margin where local fail-
ure is common. MIT, as we have termed it, is being
evaluated in a phase I trial at our institution, where
patients with surgically resectable PA receive 30 Gy in 1
fraction to the sub-GTV volume targeting the at-risk
margin (not the tumor) prior to proceeding to pancrea-
toduodenectomy. This dose has been previously applied
in intraoperative irradiation studies for essentially the
Figure 4 Example of Cyberknife plan in axial and sagittal planes.
Table 4 Significant dosimetric outcomes observed when comparing 3DSBRT, IMRT, and CK planning techniques
Organ Parameter Dose 3DSBRT
(cGy)
Range
(cGy)
Dose CK
(cGy)
Range
(cGy)
Dose MRT
(cGy)
Range
(cGy)
p
value
Superior
Modality
L kidney Mean dose 172.7 80-294 148.0 86-249.8 297.3 183.4-410.4 < 0.001 3DSBRT and CK
L renal vessels Mean dose 629.8 101-1431 828.0 178-1585 952.5 104.3-
1621.7
< 0.001 3DSBRT
R kidney Mean dose 109.1 50-220 81.5 41-150 217.7 66-429 0.007 3DSBRT and CK
R renal vessels Maximum
dose
1508.5 764-2503 1306.7 310-2566 2063.5 981-2984 0.001 3DSBRT and CK
R renal vessels Mean dose 460.6 130-858 622.3 87-2380 909.2 253-1878 0.003 3DSBRT
Celiac trunk Maximum
dose
3284.9 1954-3754 3371.9 2880-3904 2958.8 2681-3286 0.007 IMRT
Duodenum Mean dose 509.5 305-745 276.6 106-543 371.2 230-717 < 0.001 CK and IMRT
Duodenum Dose to 5 cc 1108.6 840-1310 779.7 380-1273 845.9 598-1047 0.010 CK and IMRT
Liver Mean dose 108.7 67-178 111.7 42-218 82.1 37-128 < 0.001 IMRT
SMA Maximum
dose
3551.0 2754-3815 3572.6 1618-4147 3068.0 1861-3373 0.001 IMRT
SMA Mean dose 2951.8 913-3619 2999.4 859-3905 2745.7 533-3123 0.015 IMRT
Transverse
colon
Dose to 20
cc
582.9 203-916 408.5 0-844 769.5 454-1134 0.003 CK
Dosimetric
value
Definition Ratio value Range Ratio value Range Ratio value Range p
value
Superior
Modality
Conformality
index
Ratio 1.29 1.16-1.50 1.19 1.14-1.23 1.15 1.06-1.18 < 0.001 CK and IMRT
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sub-GTV in our study [33]. Patients will receive adju-
vant systemic chemotherapy after surgical resection as is
normally practiced in the U.S. We will evaluate preo-
perative acute toxicity related to SABR delivery as well
as post-operative mortality in hopes of characterizing
the associated toxicities of this novel idea. We will also
characterize secondary endpoints such as surgical mar-
gin positivity and local control rates.
The first aspect of our study evaluated motion of
regional structures around the sub-GTV to characterize
appropriate margins. Because the sub-GTV represents
an area along the retroperitoneal margin and is not a
discrete structure such as the tumor volume itself (as in
SABR for lung cancer), motion of this margin must be
determined by the motion of adjacent structures on
which the margin is based. For the sub-GTV volume in
this case, the SMA itself most likely represents the
motion associated with the sub-GTV volume. We have
hypothesized that motion of the SMA would be small,
but there are no detailed descriptions within the current
literature evaluating this motion. As expected, mean
motion of the SMA was small in any one direction (< 3
mm) (Table 1), and was not significantly affected by AC.
Yet, vector motion of the SMA was significantly reduced
by AC in our study of 10 patients. Because the motion
of the SMA is not evaluable prior to simulation utilizing
fluoroscopy, the use of AC within the trial is based on
pre-simulation fluoroscopic evaluation of fiducial
motion. Fiducials are placed in the head of the pancreas
prior to simulation and motion of these fiducials has
been > 5 mm on fluoroscopy without compression in all
four patients enrolled on the trial thus far. AC has been
used in these patients to reduce this motion, but the
effect of AC on SMA motion was not known until this
study was initiated. Other regional respiratory-associated
organ motion has been well characterized within the lit-
erature utilizing several types of methods including
ultrasound, fluoroscopy, or 4DCT [34-39]. In addition,
the effect of abdominal compression on organ motion
has also been characterized [25,36]. Smaller overall
o r g a nm o t i o ns e e ni no u rs t u d ym a yb ed u et ot h e
methods used in both breathing instruction and evalua-
tion of movement. Our study did not include an audio
respiratory coach such as was used in the Brandner et
al. study [40]. An audio coach instructing the patient
when to inspire, may actually cause an increase in
respiratory amplitude and thus greater respiratory move-
ment than without a coach [41]. Audio and audiovisual
coaching has been shown to make the respiratory cycle
more reproducible, but may be one reason for slightly
increased respiratory associated organ motion in studies
using this method [41]. In general, the relatively low
amplitude organ motion seen with free breathing in this
region was reduced, although not significantly with the
u s eo fA C .I na d d i t i o n ,t h e r em a yb ead i f f e r e n c ei n
motion of surrounding organs due to the presence of a
pancreatic head tumor and associated mass effect from
the desmoplastic reaction often associated with these
tumors. Some of the patients analyzed for motion did
not have pancreatic tumors, and thus may have different
motion characteristics. After further analyzation, how-
ever, we found no significant difference in the organ
motion amplitude for the patients with or without pan-
creatic tumors. The tumors treated with the radiation
approach described in this manuscript are resectable
and thus in general likely to be low-volume tumors. By
definition, they are not attached directly to any sur-
rounding organs other than the duodenum. Because of
limitations of this study including patient number, single
time point 4DCT acquisition, and inherent errors
related to 4DCT acquisition and reconstruction,[41] we
will continue to evaluate motion on a individual patient
basis to determine the appropriate use of AC in this
setting.
In addition to evaluating the motion effects of AC, it
is clear that the AC plate itself displaces abdominal
organs causing displacements and deformations. There
was some concern that displacement of structures such
as the stomach and transverse colon towards the sub-
GTV target could increase dose to these structures.
Thus, identical plans were performed on planning CT
scans both with and without abdominal compression to
see the effect of the compression plate on OAR dose. As
shown in Table 2, no significant changes were seen in
mean dose to any of the regional OARs including the
stomach and traverse colon. We also did analysis on
minimum, maximum, and dose to various volumes of
OARs (not shown), which also did not change signifi-
cantly with the application of abdominal compression.
A g a i n ,t h ep r e s e n c eo ra b s e n c eo fap a n c r e a t i ct u m o r
could affect the effect of AC on surrounding organs in
this heterogeneous patient population. Yet, on further
analysis, no dosimetric difference was seen when the
patients were separated into those with or without pan-
creatic tumors. Based on this data, we are reassured that
AC can be applied safely to control motion in SABR of
the pancreas without potentially increasing dose signifi-
cantly to regional OARs of interest.
Finally, because SABR to this region had not been per-
formed at our institution prior to initiation of this study,
little was known about the best planning technique for
delivery of single fraction ablative radiotherapy to the
planned volume of interest. Thus, we compared doses to
regional OARs for three different planning methods
including non-coplanar 3DSABR, coplanar IMRT, and
CK. Various significant results for OAR dose were high-
lighted in the results section. In general, non-coplanar
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Page 9 of 11strategies like 3DSABR and CK were able to reduce dose
to vessels or structures in axial plane of the PTV such
as the renal vessels and kidneys because these techni-
ques enable a more isotropic dose falloff, especially in
the axial plane [26]. It is important to state that objec-
tives for the kidneys and renal vessels were nonetheless
met in all plans such that toxicity is unlikely to be
affected by observed differences. 3DSABR and CK had
higher doses to vessels immediately adjacent to the PTV
including the celiac trunk and SMA. This difference is
likely associated with the prescription method of each
planning technique. 3DSABR and CK were typically pre-
scribed to the 60-80% isodose line, while IMRT was pre-
scribed to 95-100% of the PTV maximum dose. Often, a
portion of the SMA and celiac trunk are included in the
PTV volume after expansion. Thus, hot spots within the
PTV itself can affect maximum doses to the SMA and
celiac trunk. The tolerance of vessels such as the SMA
to external beam irradiation is informed in part by
experience from intraoperative irradiation studies [42].
Radiation tolerance of the superior mesenteric plexus is
less well appreciated. Patients will be monitored long
term for such rarely reported toxicities as infarction
from vessel atherosclerosis or aneurysm development, as
well as autonomic neural effects. IMRT was also able to
improve upon dose to the liver and transverse colon,
organs at further distance from the target volume than
those discussed thus far. Again, specific constraints for
single fraction SABR were met for these structures for
the other planning methods, and thus no conclusions
on correlation to toxicity can be made. Finally, CK and
IMRT both improved CI over 3DSABR. The PTV
volume described has a concave portion, limiting
3DSABR’s ability to achieve a high conformality index,
unlike typical tumors, which are spherical. Thus, the
ability of CK and IMRT to shape dose around concav-
ities lead to significantly better CI in these ten patients.
From our limited study, no superior planning method
was determined. Because of increased conformality and
reduced dose to adjacent vessels, IMRT planning techni-
que is utilized at our institution thus far for treatment
on this clinical trial.
Conclusions
In conclusion, this study introduces a new treatment
concept, coined MIT, to preoperatively treat the retro-
peritoneal margin in resectable PA to a single high dose
of radiation and is being evaluated in a phase I trial at
our institution. In preparation for opening this trial, we
have examined several novel aspects related to radiation
planning techniques including regional respiratory-asso-
ciated motion that may affect target coverage and plan-
ning margins and the effect of AC on this motion. In
addition, we have determined that AC does not affect
the dose to regional OARs around our PTV. Finally, we
have evaluated three different planning techniques to
deliver single fraction SABR to this region, and
described strengths and weaknesses of each technique.
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